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1. Introduction 
Secreted phospholipases A2 (sPLA2s) constitute a large family of interfacial enzymes that 
hydrolyze the sn-2 ester bond of membrane glycerophospholipids, releasing free fatty acids 
and lysophospholipids (Murakami et al., 2011). They are abundant in snake venoms, 
frequently being their major toxic components, and display a variety of pharmacological 
effects, such as neurotoxicity, myotoxicity, anticoagulant activity, cardiotoxicity and 
haemolytic activity. The molecular mechanisms underlying these effects are still poorly 
understood; but they are most probably based on the existence of specific, high-affinity 
binding sites for toxic sPLA2s on the surface of target cells in specific target tissues (Kini, 
2003). Snakes have developed, through evolution, an arsenal of structurally similar 
molecules that target a specific tissue or function, in order to capture and digest their prey. 
Interestingly, very often a particular sPLA2 molecule may display, despite its simple, 
globular and compact structure, several different toxic activities. Thus, it significantly 
expands the possible prey-damaging mechanisms of the venom, which also depend on the 
type of prey, site of injection of the toxin and the tissue involved. The remarkable variety of 
pharmacological effects exerted by sPLA2 toxins is a consequence of several factors that have 
intrigued scientists working in the field, but have also greatly complicated the study of their 
actions. The complications include (1) the apparently indiscriminate enzymatic activities of 
sPLA2 toxins on different cellular and non-cellular phospholipid membranes and 
aggregates; (2) the diverse effects of the products of the hydrolysis of sPLA2 toxins, 
especially on membrane structural integrity and dynamics, thus affecting the major 
structural and functional features of the cell; and (3) the ever increasing diversity of sPLA2 
intra- and extracellular binding proteins discovered in mammalian tissues, which are 
involved in very different biological processes. Additionally, many of the actions of sPLA2 
toxins involve complex, multi-step molecular mechanisms, in which a specific combination 
of enzymatic activity and/or protein binding is probably essential for a particular step. 
Although sPLA2s are structurally highly conserved proteins, it is clear that subtle 
evolutionary changes of residues on the surface of the molecule have empowered these 
enzymes with this wide range of toxic activities. Their ability to recognize specific molecular 
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targets has been gradually optimized and thus interferes with a range of physiological 
processes (Kini & Chan, 1999). Snakes have even developed, through their evolution, 
catalytically inactive sPLA2-homologues specialized in membrane damage that occurs 
independently of enzymatic activity (Lomonte et al., 2009). Interestingly, a range of 
structurally very similar sPLA2 enzymes, as well as an enzymatically inactive sPLA2 
homologue, are also present in mammals. The mammalian sPLA2 family consists of 10 or 11 
enzymes (Lambeau & Gelb, 2008) that display different cell- and tissue-specific expression 
patterns. The proteins act with a broad range of enzymatic activities on a variety of cellular 
and non-cellular phospholipid membranes (Murakami et al., 2011). They bind with high 
affinity to various soluble and membrane protein targets, many of which were discovered 
using toxic sPLA2s (Pungerčar & Križaj, 2007; Valentin & Lambeau, 2000). Furthermore, 
apart from their direct effects on membrane structure and function, the products of their 
catalysis are precursors of hundreds of bioactive lipid signalling molecules, such as the 
eicosanoids. The mammalian sPLA2 enzymes display a similarly broad range of roles, 
mostly incompletely understood and often contradictory, in various physiological and 
pathophysiological processes, such as lipid digestion and homeostasis, innate immunity, 
inflammation, fertility, blood coagulation, asthma, atherosclerosis, autoimmune diseases 
and cancer (Lambeau & Gelb, 2008; Murakami et al., 2011). In this they are analogous to 
their venom counterparts, owing their functions to a combination of enzymatic activity, 
direct and indirect effects of the products of their hydrolysis, and specific interactions with 
molecular partners inside or outside the cell. The research on the action of exogenous snake 
venom sPLA2 enzymes, which target particular physiological processes in their mammalian 
prey, has been providing important clues for deciphering the biological roles of the 
mammalian endogenous sPLA2 enzymes as well (Rouault et al., 2006; Valentin & Lambeau, 
2000).  
The most potent sPLA2 toxins display presynaptic (ß-)neurotoxicity by attacking the 
presynaptic site of neuromuscular junctions. The venom of the nose-horned viper, Vipera 
ammodytes ammodytes, contains three presynaptically neurotoxic sPLA2s, ammodytoxins 
(Atxs) A, B and C, two non-toxic ammodytins (Atns), AtnI1 and AtnI2, and a myotoxic and 
catalytically inactive Ser49 sPLA2 homologue, ammodytin L (AtnL). They are all group IIA 
sPLA2s. The presynaptically acting (ß-neurotoxic) Atxs interfere specifically with the release 
of acetylcholine from motoneurons and cause irreversible blockade of neuromuscular 
transmission. The exact mechanism of their action is not yet fully understood, but it must 
include specific binding to receptor(s) on the presynaptic membrane and enzymatic activity 
(Montecucco et al., 2008; Pungerčar & Križaj, 2007). The binding to highly specific, and yet 
unknown, primary molecular targets of ß-neurotoxins (ß-ntxs) on the presynaptic 
membrane is most probably followed by entry of the toxin into the nerve cell (Logonder et 
al., 2009; Pražnikar et al., 2008; Rigoni et al., 2008). It has been proposed that different sPLA2-
toxins exploit different internalization routes (Pungerčar & Križaj, 2007). In the motoneuron, 
they may impair the cycling of synaptic vesicles by phospholipid hydrolysis and by binding 
to specific intracellular protein targets, like calmodulin (Kovačič et al., 2009, 2010; Šribar et 
al., 2001) and 14-3-3 proteins (Šribar et al., 2003b) in the cytosol, and R25 (Šribar et al., 2003a) 
in mitochondria. Although the role of enzymatic activity in ß-neurotoxicity of sPLA2s is still 
somewhat controversial, accumulated results speak largely in favour of its being 
indispensable for full expression of the ß-neurotoxic effect (Montecucco et al., 2008; 
Pungerčar & Križaj, 2007; Rouault et al., 2006).  
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In spite of numerous attempts to identify the surface residues of sPLA2s crucial for a 
particular pharmacological effect (i.e., the “ß-neurotoxic site” or the “anticoagulant site”) ‒ 
based initially on structural analysis, chemical modification and, later on, site-directed 
mutagenesis, the molecular basis of their toxicity has yet to be resolved (Kini, 2003; Križaj, 
2011; Pungerčar & Križaj, 2007; Rouault et al., 2006). We have addressed this issue in studies 
based on protein engineering of the nosed-horned viper sPLA2s. These have resulted in 
more than fifty mutants and chimeric sPLA2 proteins that have been produced and 
characterized in terms of their biochemical and biological activities (most of them are shown 
in Table 1). The site-directed mutagenesis studies have provided answers to, or at least 
significantly improved, our knowledge concerning many important questions regarding the 
toxic and enzymatic activities of Atxs and other sPLA2s, such as:  
 Which regions of the molecule are important for the ß-neurotoxicity of Atxs and 
homologous toxic sPLA2s? 
 Which surface residues of Atxs are crucial for interaction with their high-affinity 
binding proteins? Is there a correlation between the affinity for binding to a particular 
protein target and the neurotoxic potency of Atxs, suggesting a role for the receptor 
protein in the process? 
 Which residues are responsible for interfacial membrane binding of Atxs? How do the 
interfacial membrane and kinetic properties of Atxs influence their toxic action? How 
do the enzymatic properties of Atxs compare with those of the best-studied mammalian 
sPLA2s? 
 What is the importance of the loss in evolution of enzymatic activity in the case of the 
AtnL and other myotoxic sPLA2-homologues? 
The results obtained have contributed significantly to a better understanding of the 
molecular mechanisms of action of snake venom sPLA2s and provided clues to the action of 
the homologous groups of mammalian sPLA2s.  
2. Search for the “neurotoxic site” and the role of enzymatic activity 
The significant structural similarities of toxic and non-toxic sPLA2s, which differ in their 
pharmacological actions, have enticed a large number of researchers hoping to find the 
“holy grail” of sPLA2-toxin research – the toxic site. The site is presumed to comprise only a 
small number of crucial amino acid residues (Kini, 2003). To explain the wide range of 
pharmacological effects induced by snake venom sPLA2s, Kini & Evans (1989) proposed a 
model comprising specific “target sites” present on the surface of particular cell types. The 
target sites are proposed to be recognized by complementary “pharmacological sites” on the 
toxin molecule, these being structurally distinct from, and independent of, the “catalytic 
site.” Thus, high-affinity binding (at least in the nM range) of the toxin to specific target sites 
ensures that, upon entering the circulation, each toxin binds primarily to its proper target 
tissue. It is highly likely that the primary target, or acceptor, sites are proteins. This is 
because of the much lower affinity (mM–µM range) of sPLA2s for binding to the abundant 
zwitterionic phospholipid surfaces (i.e., cell membranes) (Bezzine et al., 2002; Petan et al., 
2005; Singer et al., 2002) and, following enzyme adsorption to the membrane surface, 
indiscriminate binding to and hydrolysis of phospholipid molecules at the catalytic site. 
Therefore, separate pharmacological sites on an sPLA2 molecule recognizing different target 
binding sites should be the main structural determinants that differentiate their respective 
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pharmacological actions, such as presynaptic or central neurotoxicity. However, according 
to the results of our mutagenesis structure-function studies of Atxs reviewed below, it is 
unlikely that there is a structurally distinct, single “presynaptic neurotoxic site” located in a 
specific part of the molecule, in contrast to the strict physical localization of the enzyme 
active site. Rather, different parts of the toxin molecule are likely to be involved in different 
stages of the complex multi-step process of neurotoxicity, all contributing to the final 
outcome. In this view, structurally different ß-ntxs may have different surface regions that 
bind to different (extra- and intracellular) targets, which are nevertheless involved in the 
same process, most probably the recycling of synaptic vesicles. However, they all share the 
nonspecific sPLA2 activity, i.e., the ability to bind and hydrolyze different phospholipid 
molecules embedded in membranes of various compositions ‒ an essential step in the 
complete, irreversible blockade of neuromuscular transmission. Therefore, at least in the 
case of ß-neurotoxic sPLA2s, the use of the term “presynaptic neurotoxic site” appears 
unsuitable for describing the multiple regions distributed on the surface of the sPLA2 
molecule (Prijatelj et al., 2008). 
Given the multi-step, and as yet incompletely known, molecular events leading to 
presynaptic neurotoxicity of sPLA2s, a simple correlation between their in vitro enzymatic 
activity and their lethal potency would not be expected (Rosenberg, 1997). Indeed, there are 
numerous examples of sPLA2 ß-ntxs with significantly different enzymatic properties, 
which are, however, not reflected in differences in toxicity; in fact even the most potent 
sPLA2 ß-ntxs are weak enzymes (Petan et al., 2005; Pražnikar et al., 2008; Prijatelj et al., 
2006b, 2008; Rosenberg, 1997). Nevertheless, sPLA2 enzymatic activity is necessary for full 
expression of the ß-neurotoxic effect (Montecucco et al., 2008; Pungerčar & Križaj, 2007). Its 
role in the process is most probably obscured by the numerous factors affecting both sPLA2 
activity and neurotoxicity, especially the, as yet unknown, (sub)cellular location, 
accessibility, composition and physical properties of the target membrane. The enzymatic 
action of sPLA2s could lead to structural and functional destruction of cell membranes and 
organelles, like mitochondria or synaptic vesicles (Pražnikar et al., 2008, 2009; Pungerčar & 
Križaj, 2007; Rigoni et al., 2008), since the products of phospholipid hydrolysis are 
disruptive to many physiological processes by impairing the function of peripheral and 
integral membrane proteins and promoting membrane dysfunction by altering membrane 
asymmetry, curvature and fusogenicity (Montecucco et al., 2008; Paoli et al., 2009; Rigoni et 
al., 2005). The apparent lack of correlation between in vitro enzymatic activity and lethal 
potency of Atxs or other neurotoxic sPLA2s (Montecucco et al., 2008; Petan et al., 2005; 
Pungerčar & Križaj, 2007) can be explained by the strict localization of the sPLA2 activity to 
particular target membrane(s) due to binding to highly specific extra- and intracellular 
protein acceptors (Paoli et al., 2009; Petan et al., 2005; Pungerčar & Križaj, 2007). Our studies 
investigating the interfacial binding and kinetic properties of toxic sPLA2s and their mutants 
have provided important clues to understanding the role of enzymatic activity in the 
process of presynaptic neurotoxicity of sPLA2s. As described in detail below, despite their 
potent neurotoxic activity, Atxs are quite effective in hydrolysing pure phosphatidylcholine 
(PC) vesicles as well as PC-rich plasma membranes of mammalian cells, similarly to the 
most active mammalian group V and X sPLA2 enzymes (Petan et al., 2005, 2007; Pražnikar et 
al., 2008). We have also shown that, when tightly bound to the membrane surface, the Ca2+ 
requirements of Atxs are in the micromolar range (Petan et al., 2005), opening up the 
possibility that such neurotoxins are also catalytically active in the subcellular 
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compartments where Ca2+ concentrations are low (Kovačič et al., 2009; Petan et al., 2005). 
Moreover, Atxs are rapidly internalized in motoneuronal cells and are, surprisingly, 
translocated to the cytosol, where they specifically bind calmodulin (CaM) and 14-3-3 
proteins, strongly opposing the dogma of the exclusively extracellular action of not only 
sPLA2-neurotoxins, but also of sPLA2s in general (Pražnikar et al., 2008). In agreement with 
these findings, we have recently shown that high-affinity binding to the cytosolic Ca2+-
sensor molecule CaM leads to structural stabilization (increased resistance to the reducing 
environment of the cytosol) and a significant augmentation of the enzymatic activity of Atxs 
and, intriguingly, also of the mammalian group V and X sPLA2s (Kovačič et al., 2009, 2010). 
These findings strongly support the possibility of augmentation of Atx enzymatic activity by 
CaM in the cytosol during the process of ß-neurotoxicity. They also point to a new 
mechanism of modulating the enzymatic activity of mammalian group V and X sPLA2s or 
some other non-toxic endogenous sPLA2 (Kovačič et al., 2010).  
3. Structural determinants of presynaptic neurotoxicity of sPLA2s 
The subtlety of the structure-function relationship of sPLA2 neurotoxins is obvious on 
examination of the primary structures and toxicities of Atxs. The three sPLA2 toxins each 
consist of 122 amino acid residues and differ at only five positions (Križaj, 2011). AtxC may 
be considered as a natural double mutant (F124I/K128E) and AtxB as a triple mutant 
(Y115H/R118M/N119Y) of AtxA. Nevertheless, their lethal potencies in mice differ 
considerably. AtxA is the most lethal; and its protein isoforms, AtxC and AtxB, are 17- and 
28-fold less potent, respectively (Thouin et al., 1982). The crystal structures of recombinant 
AtxA (PDB code 3G8G) and natural AtxC (PDB code 3G8H) demonstrate the absence of 
significant structural differences between the two toxins (Saul et al., 2010). There is only a 
minor conformational difference at positions 127 and 128 in the C-terminal region, caused 
by the charge-reversal substitution of Lys128 for Glu, which does not significantly influence 
the toxicity (Saul et al., 2010). An illustrative example of the subtle structure-function 
relationships of sPLA2s is the conversion, by a single mutation (F22Y), of the gene for bovine 
pancreatic group IB sPLA2 to a gene encoding a molecule able to compete with crotoxin, a ß-
neurotoxic sPLA2 from the South American rattlesnake, Crotalus durissus terrificus, for 
binding to its 45-kDa neuronal-binding protein. This led the authors to suggest the 
conversion of the non-toxic pancreatic sPLA2 to a neurotoxic molecule (Tzeng et al., 1995). 
By substituting several basic residues in the C-terminal region (AtxANNTETE mutant: AtxA-
K108N/K111N/K127T/K128E/E129T/K132E) and in the ß-structure region (AtxASSL 
mutant: AtxA-K74S/H76S/R77L) with acidic and non-ionic residues, we have shown, 
contrary to previous beliefs, that the basic character of Atxs, and probably of other ß-
neurotoxic sPLA2s, is not obligatory for presynaptic toxicity (Ivanovski et al., 2004; Prijatelj 
et al., 2000; Table 1). According to our earlier structure-function analyses, the more than one 
order of magnitude lower toxicity of AtxC than that of AtxA is a consequence of the 
substitution of the aromatic Phe124 by Ile (Pungerčar et al., 1999). Furthermore, in 
accordance with the three substitutions responsible for the difference in toxicities of AtxA 
and AtxB, several other C-terminal residues of AtxA, namely the Tyr115/Ile116/ 
Arg118/Asn119 (YIRN) cluster, were shown to be important for the neurotoxicity of Atxs 
(Ivanovski et al., 2000). Thus, the lethal potency of the AtxA-Y115K/I116K/R118M/N119L 
(AtxAKKML) mutant was 290-fold lower than that of AtxA (Ivanovski et al., 2000 and Table 1). 
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sPLA2 LD50  (g/kg)  IC50 (nM)  References 
CaM R25 R180 
AtxA 21 6  2 10  3 16  3 a, b 
AtxB 580 23  4 n. d. n. d. a, c 
AtxC 360 21  3 50 155 a, c, d, e 
12-AtxA 280 72  15 5  2 > 104 f 
I-AtxA 500 250  60 3.4  0.3 > 104 f 
P-AtxA 420 380  85 3.5  0.5 > 104 f 
AtnI2/AtxAK108N > 104 1300  200 20  6 490  100 g 
AtnI2N24F/AtxAK108N > 5000 1700  300 24 6 850  200 g 
AtnI2 > 104 > 104 > 104 610  100 g 
AtxANNTETE 660 27  5 16 100 c, d 
AtxAK108N/K111N 67 17  4 38 68 c, d, h 
AtxAK127T 35 20  3 22 300 c, d 
AtxAK128E 45 14  3 n. d. n. d. c, h 
AtxAF24A 90 7.0  0.9 15  1 17  2 b 
AtxAF24N 2800 5.6  0.7 14  2 26  1 b 
AtxAF24S 380 7.4  0.2 14  1 16  2 b 
AtxAF24W 175 13.6  0.3 37  5 26  3 b 
AtxAF24Y 330 9.2  0.9 14  3 19  4 b 
AtxAV31W 135 n. d. n. d. n. d. i 
AtxAR72E 84 71  3 14  1 78  7 j 
AtxAR72I 32 17  2 18.0  0.4 28  3 j 
AtxAR72K 50 46  2 11.7  0.4 83  9 j 
AtxAR72S 55 24  2 16  1 35  1 j 
AtxASSL 276 18  1 18  1 107  8 j 
AtxAK86A 24 8.1  0.3 15  1 20  3 j 
AtxAK86E 32 7  1 18  1 42  4 j 
AtxAK86G 34 7.5  0.2 12.1  0.1 65  4 j 
AtxAK86R 31 8.8  0.5 16.3  0.5 36  1 j 
AtxAKKML ~ 6000 50  9 86 257 c, k 
AtxAKK ~ 5000 21  3 380 118 c, k 
AtxA/DPLA2YIRN 45 27  5 180  25 100  16 l 
AtxAKEW/DPLA2YIRN 910 43  12 110  15 22  4 l 
AtxAKE/DPLA2YIRN 790 14  4 87  9 24  4 l 
AtxAW/DPLA2YIRN 107 28  7 78  12 19  5 l 
AtxA/DPLA2 2600 110  10 45%# 280  19 l 
DPLA2YIRN ~ 17000 43  14 200  30 120  21 c, l 
DPLA2 3100 300  36 75%# 300  45 c, l 
AtnL > 10000 n. d. n. d. n. d. m 
AtnLYVGD > 7000 n. d. n. d. n. d. m 
AtnLYWGD 2200 n. d. n. d. n. d. m 
Table 1. Lethal potency and protein-binding affinity of Atxs, Atns, DPLA2 and their 
mutants. IC50 values (the concentration of competitor sPLA2 required to reduce the binding 
of 10 nM 125I-AtxC by 50%) were determined from competition binding experiments for 
binding to calmodulin (CaM), the mitochondrial receptor R25 and the neuronal M-type 
sPLA2 receptor, R180. #The recombinant toxin did not completely inhibit the binding of 125I-
AtxC. aThouin et al., 1982; bPetan et al., 2002; cPrijatelj et al., 2003; dPrijatelj et al., 2000; eČopič 
et al., 1999; fPrijatelj et al., 2006b; gPrijatelj et al., 2002; hPungerčar et al., 1999; iPetan et al., 
2005; jIvanovski et al., 2004; kIvanovski et al., 2000; lPrijatelj et al., 2008; mPetan et al., 2007. 
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The KKML cluster is present in the weakly neurotoxic DPLA2 from the venom of Russell’s 
viper, Daboia (Vipera) russelii russelii, which shares a high level of amino acid identity (82%) 
with AtxA. However, the latter is almost 150-fold more toxic in mice (Prijatelj et al., 2003). 
To our great surprise, the introduction of the YIRN cluster into DPLA2 did not increase its 
toxicity; on the contrary, the DPLA2YIRN mutant was more than five times less toxic than 
DPLA2 (Prijatelj et al., 2003). Additionally, our study on the importance of the N-terminal 
residue Phe24, in which it was replaced by other aromatic (tyr or trp), polar uncharged (ser 
or asn) or hydrophobic (ala) residues, suggested that Phe24 is also involved in the 
neurotoxicity of Atxs, apparently at a stage not involving enzymatic activity or interactions 
with the high-affinity binding proteins R25, R180 and CaM (Petan et al., 2002). The aromatic 
Phe24 was chosen for this study on the basis of several interesting characteristics. It is 
located in a region immediately preceding the Ca2+-binding loop, but it is spatially close to 
the important Phe124. It is important for membrane binding as part of the interfacial 
binding surface (IBS, see below) of the enzyme, and it is replaced by ser in the weakly 
neurotoxic DPLA2. These facts prompted us to propose that a particular combination of both 
C-terminal and N-terminal residues must be involved in ß-neurotoxicity. In order to identify 
the N-terminal residues that supplement the role of the YIRN cluster in the high neurotoxic 
potency of AtxA, we selectively mutated some of the remaining residues that differentiate 
DPLA2 from AtxA. First, we introduced the N-terminal half of AtxA into DPLA2 by 
preparing the chimeric AtxA/DPLA2 protein. Its lethal potency was relatively low, in the 
range of those of DPLA2 and the AtxAKKML mutant (Table 1 and Ivanovski et al., 2000), 
confirming that it is primarily the presence of the KKML cluster in the C-terminus of the 
chimera that has a strong negative influence on toxicity. Secondly, by substituting the 
KKML cluster in DPLA2 with the YIRN cluster of AtxA, we produced a chimeric mutant 
(AtxA/DPLA2YIRN) that is 58-fold higher in lethal potency than is AtxA/DPLA2, reaching a 
level of toxicity similar to that of the highly neurotoxic AtxA. Thus, only in combination 
with the N-terminal part of AtxA is the presence of the YIRN cluster sufficient for the high 
neurotoxic potency of AtxA and AtxA/DPLA2YIRN. This allowed us to exclude the 
importance of the additional eleven C-terminal residues present in AtxA and absent in 
DPLA2 ‒ Thr70, His76, Glu78, Gly85, Arg100, Asn114, Ser130, Glu131 ‒ and was in 
accordance with the findings of our early mutagenesis study on the three C-terminal lysines 
at positions 108, 111 and 128 (Pungerčar et al., 1999) (Figure 1). These results clearly 
confirmed our hypothesis that a particular combination of C-terminal residues, especially 
those in the region 115-119, i.e., the YIRN cluster, and certain N-terminal residues are 
necessary for the potent ß-neurotoxicity of Atxs.  
Our next objective was to determine the contribution to the high neurotoxic potency of AtxA 
of the remaining nine N-terminal residues that differentiate it from DPLA2 (Met7, Gly11, 
Asn17, Pro18, Leu19, Thr20, Phe24, Val31 and Ser67). As described above, the importance of 
the aromatic Phe24 had already been established (Petan et al., 2002). In order to assess the 
importance of the remaining N-terminal residues, we first substituted Met7, Gly11 and 
Val31 in the highly toxic chimera AtxA/DPLA2YIRN by the corresponding residues present in 
DPLA2 ‒ lys, glu and trp, respectively. The mutant protein AtxAKEW/DPLA2YIRN displayed a 
20-fold lower lethal potency than the AtxA/DPLA2YIRN chimera, suggesting involvement of 
the group of residues at positions 7, 11 and 31 in AtxA neurotoxicity. The lethality of the 
partial mutants, AtxAKE/DPLA2YIRN and AtxAW/DPLA2YIRN (Table 1), revealed that the 
contribution of the pair of residues in the N-terminal helix, Met7 and Gly11, to the  
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Fig. 1. Amino acid alignment of snake venom group IIA sPLA2s, including the sPLA2-
homologue ammodytin L (AtnL), some of their mutants and the human group IIA, V and X 
sPLA2s. The residues comprising the putative IBS of Atxs are presented in bold type, while 
those most important for the neurotoxicity of ammodytoxins (Atxs) are underlined. The 
weakly neurotoxic sPLA2 from Russell’s viper, Daboia r. russelii, DPLA2, differs from AtxA in 
only 22 residues (82% identity). AtnL, the enzymatically inactive but myotoxic Ser49 
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structural homologue of Atxs, displays 74% amino acid identity with AtxA. The neutral 
ammodytin I2 (AtnI2) is a non-toxic homologue of Atxs from the same venom with 58% 
amino acid identity with AtxA. Atxs also display a relatively high degree of identity (48%) 
with the human groups IIA (hGIIA), V (hGV) sPLA2s, and X (hGX) sPLA2 (41%). The 
common sPLA2 numbering of residues was used (Renetseder et al., 1985). Gaps, represented 
by dashes, were used to align the homologous sPLA2s according to conserved residues. 
Identical amino acid residues are shown by dots. Amino acid single-letter symbols are 
shown in Table 1 in the chapter by Figurski et al. 
neurotoxic potency of AtxA is substantially higher than that of Val31 ‒ in accordance with 
the negligible effect of the V31W mutation on the lethality of AtxA, despite its outstanding 
effect on enzymatic activity (Petan et al., 2005). Interestingly, the bulky Trp at position 31 of 
the AtxAV31W and AtxAW/DPLA2YIRN mutants had no significant impact on neurotoxicity, 
despite being spatially very close to Phe24 and also to the YIRN cluster. The collective 
contribution of the N-terminal residues Met7, Gly11 and Phe24 to the neurotoxicity of AtxA 
is very significant and similar to that of the YIRN cluster in the C-terminus. For example, the 
substitution of Phe24 with ser in AtxA caused an approximately 19-fold decrease in 
neurotoxicity (Petan et al., 2002), which is similar to the reduction seen after adding the N-
terminal region of AtxAKEW, in which the residues Met7, Gly11 and Val31 were substituted 
with lys, glu and trp, respectively, to DPLA2YIRN, resulting in the AtxAKEW/DPLA2YIRN 
chimeric mutant. Therefore, it is highly likely that the remaining N-terminal residues 
differentiating AtxA and DPLA2, i.e., the Asn17/Pro18/Leu19/Thr20 cluster and Ser67, are 
not greatly involved in neurotoxicity.  
Our structure-function studies of ß-neurotoxic sPLA2s (Ivanovski et al., 2000, 2004; Petan et 
al., 2002, 2005; Prijatelj et al., 2000, 2002, 2003, 2006b, 2008; Pungerčar et al., 1999) clearly 
show that different parts of the toxin molecule have separate roles in the distinct steps of the 
complex mechanism of presynaptic neurotoxicity (Pungerčar & Križaj, 2007). Most 
significantly, by selectively mutating parts of the DPLA2 molecule, we were able to map the 
residues that separate the weakly ß-neurotoxic sPLA2 from the 150-fold more potent AtxA 
(Prijatelj et al., 2008). In summary, the most important structural features responsible for the 
high neurotoxic potency of Atxs (Figure 2, A) are: the “upper” part of the molecule 
concentrated around the C-terminal region 115-119 (the YIRN cluster) and including the 
spatially close aromatic Phe124 and Phe24, and the N-terminal helix region with the 
Met7/Gly11 pair in the “lower right” part of the molecule. 
4. Enzymatic activity of Atxs: factors influencing interfacial binding and 
hydrolysis of phospholipid membranes 
Secreted PLA2s are prototypical interfacial enzymes (Berg et al., 2001). In order to gain 
access to their phospholipid substrate, sPLA2s first have to bind at the lipid/water 
membrane interface by their interfacial binding surface (IBS), a group of residues located on 
a relatively flat exposed region surrounding the entrance to the active site pocket (Lin et al., 
1998; Ramirez & Jain, 1991). Only then, after the enzyme is bound to the surface, can binding 
of a single phospholipid molecule and its hydrolysis occur in the active site. The catalytic 
turnover cycle of sPLA2s includes a highly conserved His48‒Asp99 dyad and an activated 
water molecule that acts as a nucleophile during hydrolysis of the sn-2 ester bond of the 
phospholipid (Scott et al., 1990). The resulting tetrahedral intermediate is stabilized by the  
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Fig. 2. Surface residues of ammodytoxin A (AtxA) responsible for A) presynaptic 
neurotoxicity, B) interfacial membrane binding, C) binding to calmodulin and D) binding to 
factor Xa. The molecule is oriented with the interfacial binding surface (IBS) and the N-
terminal residues facing the viewer, while the C-terminal region is located in the upper-left 
corner of the molecule; and the ß-structure, in the lower-right corner. A) The conserved 
sPLA2 helical structures are labelled with alphabet letters (red) (see section 4.1 for details; 
Saul et al., 2010). Residues important for neurotoxicity are presented in orange mesh surface 
and extend from the C-terminal region 115–119 (the YIRN cluster), including the spatially 
close aromatic Phe124 and Phe24, to the N-terminal helix region with the Met7/Gly11 pair 
in the “lower right” part of the molecule. B) The IBS residues of AtxA are presented in blue 
mesh surface (Leu2, Leu3, Leu19, Thr20, Phe24, Val31, Ser67, Lys69, Thr70, Arg72, Arg118, 
Asn119 and Phe124) and surround the active site pocket with His48 and Asp99 (presented in 
green). C) The Atx–CaM interaction surface comprises most of the C-terminal residues of 
AtxA in the region 108–131 and several basic residues in α-helices C and D (red mesh 
surface representation; more details in Kovačič et al., 2010). D) The anticoagulant activity of 
AtxA is a consequence of its binding to factor Xa, which involves mostly basic residues 
(magenta mesh surface): Arg118, Lys127, Lys128 and Lys132 in the C-terminal end and 
Arg72, Lys74, His74 and Arg77 in the ß-structure region (Prijatelj et al., 2006a). 
Ca2+ cofactor, which is coordinatively bound by three main-chain carbonyl oxygen atoms of 
residues in the conserved Ca2+-binding loop of the enzyme (Tyr28, Gly30 and Gly32) by two 
carboxylate oxygen atoms of Asp49, and by two oxygen atoms from the phospholipid 
substrate (Scott et al., 1990). Calcium ion is required for the initial binding of a phospholipid 
molecule to the active site of sPLA2s and for the catalytic step, but it is not necessary for 
adsorption of sPLA2s to the membrane (Yu et al., 1993). Given that the binding of sPLA2s to 
a membrane surface is structurally and kinetically independent of the subsequent binding 
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and catalytic steps at the active site (Berg et al., 2001), the term substrate specificity in the 
case of sPLA2s is a combination of two independent “specificities”: (1) the affinity of the 
enzyme for binding to a membrane surface, governed by the interaction of the IBS and 20‒40 
phospholipids on the surface, and (2) the relative velocity of hydrolysis of different 
phospholipid species by the membrane-bound enzyme that obeys Michaelis-Menten 
kinetics (Berg et al., 2001; Lambeau & Gelb, 2008). The latter is determined by many factors 
influencing the interactions of the substrate molecule in the active site cleft, the rate of the 
catalytic reaction and the rate of release of the reaction products. In general, the active sites 
of sPLA2s display low specificity for different phospholipid head-groups and acyl chains 
(Singer et al., 2002). As a consequence, the physiological functions of some sPLA2s, e.g., the 
human group IIA (hGIIA), V (hGV) and X (hGX) enzymes, are significantly influenced or 
even determined by their different interfacial binding specificities and not by the specificity 
of their catalytic sites (Beers et al., 2003; Bezzine et al., 2000, 2002; Pan et al., 2002; Singer et 
al., 2002). Therefore, factors influencing interfacial binding of mammalian and toxic sPLA2s, 
such as the composition and physical properties of the membrane, the nature of the IBS of 
the enzyme, and the concentration of phospholipids that are accessible to the sPLA2 
(Mounier et al., 2004), are crucial determinants of sPLA2 biological activity.  
The IBS of most sPLA2s comprises a ring of conserved hydrophobic residues, whereas, 
around them and on the edges of the IBS, some polar, basic and acidic residues are present 
(Petan et al., 2005; Snitko et al., 1997). Given that most sPLA2s have high activities on anionic 
membrane surfaces, it was long thought that electrostatic forces between cationic residues of 
the enzyme and anionic membrane phospholipids are crucial for the membrane binding and 
activity of sPLA2s (Scott et al., 1994). However, a number of studies have shown that, in fact, 
hydrophobic, aromatic and hydrogen-bonding interactions account for most of the binding 
energy, even to negatively charged membrane surfaces (Gelb et al., 1999; Ghomashchi et al., 
1998; Lin et al., 1998). Nevertheless, it has been suggested that electrostatic interactions are 
responsible for proper orientation and initial association of sPLA2s with both anionic and 
zwitterionic membranes. They may significantly modulate the dynamics of establishing 
strong hydrophobic interactions, when aliphatic and aromatic residues on the IBS penetrate 
the membrane surface, needed to form a stable sPLA2-membrane complex (Beers et al., 2003; 
Petan et al., 2005; Prijatelj et al., 2008; Stahelin and Cho, 2001). 
4.1 Basic structural, interfacial kinetic and binding properties of Atxs 
Atxs are highly basic proteins (AtxA has a pI of 10.2, net charge +6), with structural features 
typical of group IIA sPLA2 enzymes (Figure 2, A): an N-terminal α-helix A (residues 1–14), a 
short α-helix B (residues 16–22), a Ca2+-binding loop (residues 25–35), a long α-helix C 
(residues 39–57), a loop preceding an antiparallel two-stranded ß-sheet (ß-structure; 
residues 75–78 and 81–84), a long α-helix D (antiparallel to helix C; residues 89–109) and a 
C-terminal extension (mostly disordered, with two short helical turns; residues 110–133). 
The active site cleft is buried at the end of a hydrophobic channel (formed by the residues 
Phe5, Gly6, Tyr22, Ser23, Cys29, Gly30, Ala102, Ala103, Phe106) leading to the highly 
conserved His48–Asp99 dyad located between the antiparallel α-helices C and D. The 
entrance to the catalytic site of all sPLA2s is surrounded by the IBS group of residues, 
forming a relatively flat surface on one side of the molecule that is responsible for 
membrane binding – the first and prerequisite step in sPLA2 catalytic action. The IBS of Atxs 
(Figure 2, B) is formed by Leu2, Leu3, Leu19, Thr20, Phe24, Val31, Ser67, Lys69, Thr70, 
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Arg72, Arg118, Asn119, and Phe124 (Petan et al., 2005). The slight structural flexibility 
observed for the exposed side chains of residues in the IBS (e.g., Phe24 in Figure 2, B) is in 
keeping with the role of these residues in supporting optimal interactions of the molecule 
with the dynamic structure of phospholipid aggregates (Saul et al., 2010). 
According to the enzymatic activities and membrane-binding affinities of Atxs determined 
on different phospholipid vesicles, it is clear that these snake venom sPLA2s are very 
effective in binding to and hydrolyzing different phospholipid membranes (Petan et al., 
2005). This property exists despite the fact that they have evolved to be specific and potent 
neurotoxic molecules and despite the fact that they share striking structural and functional 
similarities with the mammalian (non-toxic) sPLA2s. The enzymatic activities of Atxs on 
vesicles composed of anionic phosphatidylglycerol (PG), which is, in general, the best sPLA2 
substrate, are comparable to those displayed by the most potent mammalian sPLA2, the 
pancreatic group IB sPLA2, and 5-fold higher than those displayed by the mammalian group 
IIA sPLA2s on these vesicles (Singer et al., 2002). Atxs also have particularly high activities 
on phosphatidylserine (PS) vesicles, the main anionic phospholipid in eukaryotic 
membranes, well above the activities of the group IB and IIA sPLA2s that are the most active 
mammalian sPLA2s on these vesicles. Most importantly, the activities of Atxs were high also 
on pure zwitterionic phosphatidylcholine (PC) vesicles, much higher than that of the highly 
homologous and cationic hGIIA enzyme, which cannot bind to the PC-rich plasma 
membranes of mammalian cells (Beers et al., 2003; Bezzine et al., 2000, 2002; Birts et al., 2009; 
Singer et al., 2002). The hGIIA sPLA2 is well known for its preference for anionic 
phospholipid substrates and its negligible activity on PC-rich membrane surfaces (Beers et 
al., 2003; Bezzine et al., 2000, 2002). These properties strongly influence the physiological 
role of the hGIIA enzyme, for example, by enabling its high antibacterial concentrations in 
human tears without affecting the corneal epithelial cells (Birts et al., 2009). Although the 
activities of Atxs were lower than those displayed by group V and X sPLA2s, which are by 
far the most potent among the mammalian sPLA2s in hydrolyzing PC vesicles and releasing 
fatty acids from cell membranes (Bezzine et al., 2000, 2002; Singer et al., 2002), they were 
able to hydrolyze plasma membranes of different intact mammalian cells at a rate that 
correlated well with their specific activities on PC vesicles (Petan et al., 2005; Pražnikar et al., 
2008). The high activity of Atxs on PC-rich vesicles is a consequence of the ability of these 
venom sPLA2s to bind well to such membrane surfaces, with affinities comparable to those 
of mammalian group V and X sPLA2s. Furthermore, unlike the neutral hGX and similarly to 
the highly cationic hGIIA enzyme, the presence of anionic phospholipids in the membrane 
surface greatly enhances the membrane-binding affinity of Atxs and consequently the rate 
of phospholipid hydrolysis (Bezzine et al., 2000, 2002; Petan et al., 2005, 2007). This property 
may have an important influence on both localization of the toxin to its target membrane 
and its enzymatic effectiveness in vivo. It is now clear that, when conditions of high affinity 
binding apply (i.e., binding of hGIIA or Atxs to anionic PG vesicles), sPLA2s reach their half-
maximal enzymatic activities at low micromolar concentrations of Ca2+ (Petan et al., 2005; 
Singer et al., 2002). The proposed cytosolic action of Atxs (Pražnikar et al., 2008), and most 
probably other structurally similar sPLA2s, is strongly supported by several factors. They 
may enable the enzymatic activity of Atxs in a reducing environment containing insufficient 
(nanomolar) concentrations of calcium. In support of this idea are (1) the high degree of 
stability of AtxA under conditions resembling those in the cytosol of eukaryotic cells 
(Kovačič et al., 2009; Petrovič et al., 2004), (2) the additional and very significant structural 
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stabilization and augmentation of sPLA2 enzymatic activity by CaM (Kovačič et al., 2009, 
2010), (3) the transient cytosolic microdomains of high local calcium concentrations (~100 
μM) (Meldolesi et al., 2002) or calcium entry through the damaged plasmalemma due to 
sPLA2 action prior to internalization (Montecucco et al., 2008), and (4) the presence of 
anionic phospholipids (PS) on the cytosolic face of the plasma membrane and internal 
cellular organelles (Okeley & Gelb, 2004). In conclusion, Atxs are effective enzymes that 
bind strongly to and hydrolyze rapidly both anionic and zwitterionic phospholipid 
aggregates, including mammalian plasma membranes, presenting a broad combination of 
properties characteristic of different mammalian sPLA2s. The potential for the high 
enzymatic activity of Atxs appears to be at odds with their specific neurotoxic action. 
However, it is in line with the possible limitations imposed on their intracellular activity on 
a particular target membrane by the harsh conditions in the cytosol during the process of 
neuromuscular transmission blockade.  
4.2 Role of different IBS residues in supporting interfacial binding and activity of Atxs 
The presence of tryptophan on the IBS of different sPLA2s is a well-known determinant of 
their ability to bind with high affinity and hydrolyze PC-rich membranes, crucially 
influencing their biological roles. Its role has been highlighted in the cases of the hGV and 
hGX enzymes (Bezzine et al., 2002; Han et al., 1999), the acidic sPLA2 from Naja naja atra 
snake venom (Sumandea et al., 1999), a range of mutants of hGIIA (Beers et al., 2003) and 
the pancreatic group IB sPLA2s (Lee et al., 1996). Despite the fact that Atxs do not contain a 
Trp residue, they display a relatively high activity on PC vesicles. Furthermore, the 
substitution of Val31 by Trp led to a dramatic 27-fold increase in the activity of AtxA (Petan 
et al., 2005), reaching a level of activity on PC-rich vesicles higher than those of hGV and 
hGX and in the range of the best-acting snake venom sPLA2s, e.g., the cobra venom sPLA2 
(Sumandea et al., 1999). However, despite its very high affinity for PC-rich surfaces and its 
order of magnitude higher potency in releasing fatty acids from plasma membranes of intact 
HEK293 cells, C2C12 myocytes and motoneuronal NSC34 cells (Pražnikar et al., 2008), the 
AtxA-V31W mutant did not display a major change in neurotoxic potency in vivo. This again 
highlights the dependence of the toxicity of sPLA2 ß-ntxs on a combination of toxin-acceptor 
interactions leading to localization of the toxin to the target membrane at which the 
enzymatic activity of AtxA is sufficient for the observed effects. In contrast, the same 
substitution, V31W, on the IBS of the enzymatically active quaternary mutant AtnLYVGD of 
the myotoxic Atx homologue, AtnL (see below), caused a 100-fold increase in its activity on 
PC vesicles, as well as a significant increase in its toxicity in vivo and in vitro (Petan et al., 
2007). Thus, in the case of the enzymatically active mutants of AtnL, the correlation between 
enzymatic activity on PC membranes and toxicity in vivo suggests that the mechanism of 
their toxicity differs from that used by Atxs and that it depends largely on their interfacial 
binding affinity and enzymatic activity on PC-rich target membranes, both of which are 
significantly affected by Trp31 (Petan et al., 2007).  
The role of aromatic residues in the interfacial binding of sPLA2s depends to a high degree 
on the nature of the residue itself, its position on the IBS and the orientation of its side-chain 
(Stahelin & Cho, 2001; Sumandea et al., 1999). This is evident from the fact that the 
substitution of Phe24 with Trp did not cause a substantial increase in enzymatic activity or 
interfacial binding affinity of AtxA (Petan et al., 2002, 2005) or hGIIA (Beers et al., 2003). 
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Thus, both Phe and Trp can have similar roles in interfacial binding, despite the differences 
in their interactions with the membrane: the highly amphiphilic Trp favours partitioning in 
the interfacial phospholipid head group region of the bilayer (Yau et al., 1998), while the 
aromatic Phe penetrates deeper into the hydrophobic core of the phospholipid acyl chains 
(Stahelin & Cho, 2001; Sumandea et al., 1999). In the case of AtxA and hGIIA, Trp31 is 
obviously in a much better position to influence interfacial binding than is Trp24. 
Additionally, AtxA and AtxAF24W display higher activities and binding affinities than do the 
F24S, F24Y and F24N mutants on PC-rich vesicles containing anionic phospholipids. 
Although the structures of Trp and Phe differ significantly, both are obviously better suited 
to take advantage of the presence of anionic phospholipid in the interface than the polar Ser, 
Asn and even the aromatic Tyr. The importance of non-polar interactions in interfacial 
binding to negatively charged surfaces is also clear in the case of AtxB, AtxAKKML and 
AtxAV31W. These molecules already display very high activities on PC vesicles containing 
10% PS (10% PS/PC vesicles), and they reach the level of maximal activity already on 30% 
PS/PC vesicles, indicating that the enzymes are fully bound to these vesicles (Petan et al., 
2005). In general, we have observed the greatest increases in activity upon introduction of 
10% anionic phospholipids (PS or PG) into PC vesicles for mutants that have numbers of 
hydrophobic and aromatic residues on their IBS similar to or higher than those in AtxA. 
Besides providing the basis for electrostatic interactions, the presence of anionic 
phospholipids in PC vesicles may facilitate non-polar interactions as a result of membrane 
perturbation (Buckland & Wilton, 2000).  
Despite the remarkable impact of Trp at position 31 on interfacial binding of Atxs and other 
sPLA2s, such as hGIIA (Beers et al., 2003), our subsequent site-directed mutagenesis studies 
revealed that the positive influence of Trp on membrane binding of sPLA2s may be 
significantly diminished, depending on the delicate balance of contributions of each IBS 
residue to interfacial binding. While Atxs and hGIIA sPLA2 do not contain a Trp on their IBS, 
DPLA2, a weakly neurotoxic sPLA2 from Russell’s viper that differs from AtxA in only 22 
residues, has a Trp residue at position 31 and yet displays interfacial binding and kinetic 
properties similar to those of AtxA (Petan et al., 2005; Prijatelj et al., 2003, 2008). Besides 
V31W, DPLA2 contains several other substitutions of equivalent AtxA IBS residues: L19I, 
T20P, F24S, S67N, T70S, R118M and N119L (Petan et al., 2005; Prijatelj et al., 2008). By 
analysing the properties of a range of AtxA/DPLA2 mutants and chimeras (Prijatelj et al., 
2008), we were able to pinpoint the IBS residues that are crucial for the intriguing 
differences in interfacial binding and activity of AtxA and DPLA2. Not surprisingly, the 
introduction of Trp31 to the AtxA/DPLA2YIRN chimera (see Figure 1 for sequence data) 
caused a very significant 50-fold increase in the rate of hydrolysis of PC vesicles. However, 
the impact of the same Trp residue, when introduced along with two additional 
substitutions, producing the AtxAKEW/DPLA2YIRN mutant, was almost completely abolished, 
resulting in a low level of activity on PC vesicles, only 2 to 4-fold higher than those of 
AtxA/DPLA2YIRN, AtxA and DPLA2. These results clearly confirmed our earlier suggestion 
(Petan et al., 2005) that the well-known positive impact of Trp31 on the interfacial binding 
and enzymatic activity of mammalian and venom sPLA2s is, to a large extent, 
counterbalanced by the presence of Lys7 and Glu11 on the edges of the IBS in the case of 
DPLA2, instead of the hydrophobic Met7 and nonpolar Gly11 in AtxA. This is most 
probably a consequence of altered orientation of DPLA2 on the membrane, due to strong 
electrostatic interactions between Lys7 and Glu11 and the zwitterionic membrane surface,  
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which prevents the productive interaction of Trp31, and thus DPLA2, with the interface. 
Similarly, two basic residues at nearly equivalent positions in the hGIIA enzyme, Arg7 and 
Lys10, were shown to have a negative influence on interfacial binding (Bezzine et al., 2002; 
Snitko et al., 1997). In agreement with this, we have shown that the substitution of Arg at 
position 72 of the IBS of Atxs and DPLA2 has a positive impact on interfacial binding and 
activity only upon introduction of a hydrophobic (Ile), but not a polar (Ser), acidic (Glu) or 
other basic (Lys) residue (Ivanovski et al., 2004). An additional, albeit smaller, negative 
effect on interfacial binding and enzymatic activity of DPLA2 is provided by the presence of 
the polar residue Ser24 instead of the aromatic and hydrophobic Phe in AtxA (Petan et al., 
2002, 2005). However, there are several residues on the IBS of DPLA2, but not Atxs, that 
significantly improve its interfacial binding and activity. The YIRN cluster in the C-terminal 
part of AtxA, shown to be important for its neurotoxic effect (Ivanovski et al., 2000), contains 
the hydrophilic IBS residues Arg118 and Asn119, while the hydrophobic Tyr115 and Ile116 
are not part of the presumed IBS. The introduction of the YIRN cluster into DPLA2, instead 
of its KKML cluster, or into the various AtxA/DPLA2 variants, resulted in a substantial 
decrease of the initial rates of hydrolysis of charge-neutral PC vesicles (Table 2). Therefore, 
the presence of a hydrophobic or aromatic IBS residue at positions 118 and 119 has a 
significant positive influence on interfacial binding to anionic and, particularly, zwitterionic 
phospholipid surfaces. Accordingly, this positive impact is evident in the case of Met118 
and Leu119 in DPLA2 and the AtxAKKML mutant, as well as of Met118 and Tyr119 in AtxB, in 
contrast to the hydrophilic Arg118 and Asn119 in AtxA and mutants containing the YIRN 
cluster (Ivanovski et al., 2000; Petan et al., 2005; Prijatelj et al., 2003, 2008). Considering the 
similar activities on PC-rich vesicles displayed by AtxB and the AtxAKKML mutant, it is 
obvious that the roles of Tyr and Leu at position 119 are in fact very similar. This indicates 
that the removal of the polar cluster Arg118/Asn119 from AtxA has a greater positive effect 
on interfacial binding than the aromatic or hydrophobic nature of the substituting residue at 
position 119, which is in accordance with the negligible impact of the substitution Y119W on 
interfacial binding of hGIIA sPLA2 to 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) 
vesicles (Beers et al., 2003). Thus, the role of aromatic residues, including Trp, in interfacial 
binding of sPLA2s, depends strongly, as well as on their nature, position on the IBS, and 
side-chain orientation, on the counterbalancing effects of polar/electrostatic interactions 
provided by hydrophilic/charged residues on or near the IBS. In conclusion, the most 
significant differences in interfacial binding and enzymatic activity of AtxA and DPLA2 are 
therefore a consequence of the natural substitutions that have led to significant changes in 
the hydrophobic/aromatic character of residues on or near the IBS ‒ M7K, G11E, F24S, 
V31W, R118M and N119L. 
5. Interaction of Atxs with high-affinity binding proteins 
Several high-affinity binding proteins for Atxs have been identified in porcine cerebral 
cortex. Two of these are membrane proteins of 25 kDa (R25) and 180 kDa (R180). R25, 
which is located in the mitochondrial membrane (Šribar et al., 2003a), binds only Atxs 
(Vučemilo et al., 1998), whereas R180, identified as the plasma membrane M-type sPLA2 
receptor (sPLA2R), binds both toxic and non-toxic sPLA2s of groups IB and IIA (Čopič et 
al., 1999; Vardjan et al., 2001). Surprisingly, several cytosolic, high-affinity binding 
proteins for Atxs were identified as well ‒ calmodulin (CaM) (Šribar et al., 2001), the γ and  
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sPLA2 
Specific activity (mol/(min  mg)) 
POPG POPS POPC 10% POPS/POPC 30% POPS/POPC 
AtxA 1042 ± 160 1251 ± 188 3.8 ± 0.5 56 ± 6 450 ± 21 
AtxB 1149 ± 34 1189 ± 153 14 ± 2 240 ± 22 1133 ± 150 
AtxC 1116 ± 91 477 ± 101 1.9 ± 0.2 14.0 ± 1.3 166 ± 21 
AtnI2 1070 ± 150 57 ± 5 12.3 ± 1.7 49 ± 2 159 ± 16 
AtxAKKML 1148 ± 126 1252 ± 40 19 ± 1 400 ± 22 1322 ± 42 
AtxAV31W 2102 ± 88 1964 ± 154 102 ± 7 525 ± 28 1957 ± 36 
AtxAF24W 914 ± 43 906 ± 56 4.4 ± 0.5 50 ± 1 209 ± 6 
AtxAF24Y 822 ± 41 1304 ± 102 2.1 ± 0.1 9.5 ± 0.5 163 ± 11 
AtxAF24N 780 ± 29 535 ± 43 1.09 ± 0.03 5.1 ± 0.5 68 ± 3 
AtxAF24A 813 ± 107 1291 ± 65 1.2 ± 0.1 4.4 ± 0.3 92 ± 5 
AtxAF24S 400 ± 73 430 ± 42 0.71 ± 0.06 4.4 ± 0.1 24 ± 4 
AtxAR72E 438 ± 26 n. d. 0.33  0.07 n. d. n. d. 
AtxAR72I 1655 ± 108 n. d. 6.9  0.8 n. d. n. d. 
AtxAR72K 686  102 n. d. 1.2  0.1 n. d. n. d. 
AtxAR72S 800  82 n. d. 1.6  0.3 n. d. n. d. 
DPLA2 1600  130 1195 ± 47 1.1  0.1 88 ± 9 442 ± 31 
DPLA2YIRN 1100  120 996 ± 129 0.07  0.02 4.2 ± 0.4 141 ± 20 
AtxA/DPLA2 1300  140 n. d. 3.14  0.05 n. d. n. d. 
AtxAKEW/DPLA2YIRN 1200  170 n. d. 2.2  0.5 n. d. n. d. 
AtxAKE/DPLA2YIRN 830  80 n. d. 0.14  0.01 n. d. n. d. 
AtxAW/DPLA2YIRN 1900  210 n. d. 26  3 n. d. n. d. 
AtxA/DPLA2YIRN 1000  120 n. d. 0.53  0.06 n. d. n. d. 
AtnL No activity No activity No activity n. d. n. d. 
AtnLYVGD 225 ± 35 91 ± 7 ~0.005 0.49 ± 0.04 43 ± 2 
AtnLYWGD 180 ± 25 89 ± 10 0.22 ± 0.03 8.3 ± 0.3 96 ± 5 
12-AtxA 5.2 ± 0.7 n. d. 0.76 ± 0.06 n. d. n. d. 
I-AtxA 4.0 ± 0.2 n. d. 0.96 ± 0.04 n. d. n. d. 
P-AtxA 1.29 ± 0.04 n. d. 0.13 ± 0.03 n. d. n. d. 
hGIIA 220 ± 90 40 ±18 Lag, 0.7 ± 0.2 n. d. n. d. 
hGX 14 ± 0.8 4 ± 2 30 ± 0.2 n. d. n. d. 
Table 2. Specific enzymatic activity of sPLA2s on phospholipid vesicles. The specific 
enzymatic activities were determined on extruded phospholipid vesicles composed of 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoserine (POPS), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG), and on 
vesicles with mixed compositions as stated (in molar percentage) in the Table. The initial 
rates of phospholipid hydrolysis were measured using a sensitive fluorescence, fatty acid 
displacement assay; the enzymatic activities were calculated after calibrating the responses 
with known amounts of oleic acid (Petan et al., 2005). The enzymatic activity value for each 
sPLA2 is the mean  S.D. of at least five independent measurements. Data taken from 
Ivanovski et al. (2004), Petan et al. (2005, 2007), Prijatelj et al. (2006b, 2008), and Singer et al. 
(2002). 
ε isoforms of 14-3-3 proteins (Šribar et al., 2003b), and protein disulphide isomerase (Šribar 
et al., 2005). This suggests the possibility of not only intracellular, but also cytosolic, action 
of Atxs and other sPLA2s. They have since been shown to be surprisingly stable in the 
reducing environment of the eukaryotic cytosol. They are enzymatically active at low 
micromolar concentrations of Ca2+ ions, and they are also structurally stabilized and 
activated by binding to CaM (Kovačič et al., 2009, 2010; Petan et al., 2005; Petrovič et al., 
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2005). Atxs were also found to bind factor Xa (FXa) and display anticoagulant activity 
(Prijatelj et al., 2006a). Given that the topic of neuronal high-affinity binding proteins for 
Atxs and their putative roles in ß-neurotoxicity has been reviewed recently (Pungerčar & 
Križaj, 2007), here we only summarize the results obtained with a range of Atx mutants for 
binding to CaM, R25, FXa and the M-type sPLA2 receptor. 
5.1 The C-terminal region of Atxs has a novel calmodulin binding motif 
Our protein engineering and competition binding studies using a range of Atxs, DPLA2 and 
AtnI2 mutants and chimeras, as well as synthetic peptides corresponding to different regions 
of Atxs, ultimately resulted in the identification of a novel binding motif for the ubiquitous, 
highly conserved Ca2+-sensor CaM (Kovačič et al., 2010; Prijatelj et al., 2003). The C-terminal 
region of AtxA, with a distinctive hydrophobic patch within the region 107–125 surrounded 
by several basic residues, was identified as the most important element for binding to the N-
terminal methionine-rich pocket of CaM in its Ca2+-induced dumbbell conformation. This 
work was based on the intriguing 150-fold lower lethal potency and the correspondingly 50-
fold lower CaM-binding affinity of DPLA2 compared to AtxA (Prijatelj et al., 2003). Most 
notably, the DPLA2YIRN mutant, containing the C-terminal YIRN cluster of AtxA (see above 
and Figure 1), displayed a 7-fold increase in binding affinity for CaM, only 7-fold lower than 
that of AtxA. This result suggested a major role of this region for the interaction with CaM. 
On the other hand, introduction of the whole N-terminal half of AtxA to DPLA2 and 
DPLA2YIRN caused only a slight, 2 to 3-fold increase in binding affinities for CaM, suggesting 
that the N-terminal part of AtxA has only a supporting role in the binding and is probably 
located on the periphery of the CaM binding site (Prijatelj et al., 2008). Very recently, we 
confirmed unambiguously the crucial importance of the C-terminal region of Atxs in CaM 
binding by building several three-dimensional structural models of sPLA2–CaM complexes, 
based on AtxA–CaM interaction site mapping, our previous mutagenesis data and protein-
docking algorithms (Kovačič et al., 2010). According to the model, the closed conformation 
of CaM forms a “clamp” around AtxA, with most of the C-terminal residues of AtxA in the 
region 108-131 being in direct contact with CaM (Figure 2, C). There are only a few 
additional, but important, contacts between the proteins, formed mainly by basic residues in 
α-helices C (Arg43 and Asn54) and D (Arg94, Lys108, Asn109 and Lys111) of AtxA. 
Importantly, the model was validated by superimposing the structures of several 
mammalian sPLA2s on that of AtxA in the complex and correctly predicting the favourable 
interactions of group V and X mammalian sPLA2s and CaM. The model also showed the 
basis for the unfavourable interactions, which prevented complex formation between the 
structurally very similar mammalian group IB and IIA sPLA2s and CaM. Formation of the 
complexes was confirmed by competition binding experiments and the augmentation of the 
enzymatic activity of those sPLA2s interacting with CaM. Most importantly, we have clearly 
demonstrated that CaM stabilizes and protects Atxs from denaturation in the reducing 
environment of the cell cytosol and acts as a non-essential activator of Atxs and of the 
mammalian group V and X sPLA2s. The fact that CaM-binding results in stabilization and 
augmentation of enzymatic activity of sPLA2s, ranging from the neurotoxic Atxs to the 
mammalian group V and X sPLA2s, suggests a novel role for CaM as a regulator of the 
intracellular actions of some toxic and non-toxic sPLA2s, which may be active even in the 
reducing environment of the cytosol (Kovačič et al., 2009, 2010). The significance of CaM–
sPLA2 interactions in the pharmacological and (patho)physiological roles of sPLA2s remain 
to be confirmed. 
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5.2 The N- and C-terminal regions of Atxs are involved in binding to the neuronal M-
type sPLA2 receptor (R180) 
The M-type sPLA2 receptor, which was cloned and revealed as a member of the C-type 
lectin superfamily, has been well-characterized and is currently the best-known sPLA2 
binding target. It was shown recently that the M-type receptor is involved in regulating cell 
senescence (Augert et al., 2009) and is the main antigen target in autoimmune human 
membranous nephropathy (Beck et al., 2009). However, the pathophysiological implications 
of the interaction between the M-type sPLA2 receptors and both toxic and non-toxic sPLA2s 
in general are intriguing and still unknown (Lambeau & Gelb, 2008; Pungerčar & Križaj, 
2007; Rouault et al., 2006). Although it has been suggested that the neuronal M-type sPLA2 
receptor located on the plasma membrane could be responsible for specific targeting and 
internalization of sPLA2 neurotoxins in presynaptic nerve terminals, the results of our 
mutagenesis studies have shown that it may not be involved in the neurotoxicity of Atxs 
(Prijatelj et al., 2006b). In order to prevent the interaction between AtxA and the receptor, we 
prepared three mutants of AtxA, containing either the 12-amino acid-long peptide 
ARIRARGSIEGR, named 12-AtxA, or one each of two variants of a shorter 5-amino acid 
peptide (ASIGQ and ASPGQ; named I-AtxA and P-AtxA, respectively) fused to the N-
terminus of AtxA. These peptides are similar to the N-terminal propeptides present in 
proenzymes of mammalian group IB (e.g., DSGISPR in human pancreatic proPLA2) and 
group X sPLA2s (e.g., EASRILRVHRR in the human proenzyme), which do not bind to the 
M-type sPLA2 receptor (Hanasaki & Arita, 2002; Lambeau et al., 1995). The presence of the 
fusion peptides in AtxA indeed completely abolished the interaction of the toxin with the 
M-type receptor. However, the mutants displayed only one order of magnitude lower 
lethality in mice and were able to induce neurotoxic effects on a mouse phrenic nerve-
hemidiaphragm preparation (see Table 1). Although the N-terminal fusion peptides acted 
effectively as “propeptides” for AtxA and lowered specific enzymatic activity to ~1% of the 
wild-type enzyme, their similar neurotoxic profiles on the neuromuscular junction indicate 
that minimal enzymatic activity suffices for presynaptic toxicity of sPLA2s. Additionally, 
antibodies targeting the sPLA2-binding C-type lectin-like domain 5 of the M-type sPLA2 
receptor were unable to abolish the neurotoxic action of AtxA on the neuromuscular 
preparation. Thus, the interaction of AtxA with the neuronal M-type sPLA2 receptor, R180, 
is apparently not essential for its presynaptic neurotoxicity. Since we performed the binding 
experiments with the N-terminal fusion AtxA mutants, using porcine sPLA2 receptor, the 
question still remains as to whether the fusion peptides would also abolish the binding of 
AtxA to the mouse R180 receptor. 
Nevertheless, our site-directed mutagenesis studies have provided important information 
about the parts of the AtxA molecule involved in binding to R180. Interestingly, the C-
terminal YIRN cluster, which is essential for neurotoxicity and binding to CaM and R25, 
appears to be involved in binding to R180 as well. The first clues were provided by the 
lower affinity of the AtxAKKML mutant and DPLA2 for binding to R180 (Ivanovski et al., 
2000). (Both contain KKML instead of the YIRN cluster.) The higher binding affinity of 
mutants containing the YIRN cluster (DPLA2YIRN or AtxA/DPLA2YIRN) confirmed that it is 
an important part of the AtxA/R180 interaction surface. However, other parts of the 
molecule also contribute considerably to the binding affinity of AtxA. Interestingly, the N-
terminal part of AtxA in the chimera AtxA/DPLA2 did not increase the binding affinity of 
DPLA2 to R180. However, the introduction of three N-terminal DPLA2 residues (K, E 
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and/or W) to AtxA/DPLA2YIRN caused an increase in the binding affinity for R180 up to 
the level of AtxA, confirming the expected involvement of the N-terminal part of the 
molecule in binding to R180 as well. Therefore, the interaction surface of AtxA with its 
neuronal M-type receptor, R180, extends from the C-terminal top of the molecule, across 
the area close to the Ca2+-binding loop and the IBS, reaching the N-terminal helix on the 
edges of the IBS.  
5.3 Atxs bind to the mitochondrial receptor R25 through their C-terminal region 
The C-terminal region of Atxs appears to be essential also for binding to the, as yet 
unidentified, mitochondrial membrane receptor R25. The affinities for binding of the 
chimeric mutants to R25 ranged from that of the non-toxic AtnI2, which does not bind to 
R25, to those of AtxA, AtnI2/AtxAK108N and AtnI2N24F/AtxAK108N, which were similar to that 
of AtxA (Prijatelj et al., 2002). Additionally, substitutions of Phe24 in the N-terminal part of 
AtxA had a negligible effect on its affinity for R25, but nevertheless indicated that this 
residue is in the vicinity of the toxin-receptor binding surface, most probably located in the 
C-terminal part of AtxA (Petan et al., 2002). Furthermore, while DPLA2 and the chimera 
AtxA/DPLA2 could not completely inhibit the binding of AtxC to R25 in competition 
binding experiments, the substitution of their KKML cluster with the YIRN cluster led to 
complete inhibition with a relatively high binding affinity. This implies that residues in the 
region 115–119 are very important for effective binding to R25, which is apparently present 
in multiple isoforms. However, the complete inhibition of binding of radiolabelled AtxC to 
R25 by the AtxAKKML mutant, in contrast to DPLA2 and AtxA/DPLA2, indicated that the 
interaction surface extends beyond the C-terminal region. Indeed there was a slight increase 
in binding affinity upon introduction of the N-terminal Lys7, Glu11 and/or Trp31 of DPLA2 
to the AtxA/DPLA2YIRN chimera (K, E and/or W; Table 1). While our site-directed 
mutagenesis and competition binding studies have so far revealed a central role for the C-
terminal residues of Atxs in high affinity binding to R25, the interaction surface probably 
extends beyond the C-terminal region. 
5.4 Atxs exert anticoagulant effects by binding to factor Xa 
In the analysis of non-neurotoxic effects of Atxs, our study of an array of site-directed 
mutants (Prijatelj et al., 2006a) showed that basic residues in the C-terminal and ß-structure 
regions are important for AtxA binding to human blood coagulation factor Xa (Figure 2, D). 
Hence, AtxA has anticoagulant activity. In addition, the 10-fold lower affinity of AtxC for 
factor Xa, in comparison with AtxA, is due to the (natural) charge-reversal substitution of 
Lys128 by Glu, leading to a small local conformational change in the C-terminal end of 
AtxC, which perturbs the interaction with factor Xa (Saul et al., 2010). 
6. Restoration of enzymatic activity reduces the Ca
2+
-independent membrane 
damage induced by the myotoxic ammodytin L  
Ammodytin L (AtnL) is a myotoxic and enzymatically inactive structural homologue of 
Atxs (Petan et al., 2007; Pungerčar et al., 1990). The main structural feature of snake 
venom sPLA2-like myotoxins is the substitution of the highly-conserved aspartic acid 
residue at position 49, effectively preventing Ca2+ binding and thus abolishing catalytic 
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activity (Petan et al., 2007; Ward et al., 2002). The most common substitution is Lys, but 
AtnL is one of the two known Ser49 sPLA2 homologues. In addition to this replacement, 
several other substitutions of highly-conserved residues in the enzymatically inactive 
sPLA2s are found concentrated in the region of the Ca2+-binding loop, where the 
carbonyl oxygen atoms of Tyr28, Gly30 and Gly32 provide three additional coordinative 
bonds for Ca2+-binding. The myotoxic activity of the Lys49 sPLA2s, as well as of the 
Ser49-containing AtnL, is best characterized by their ability to induce myonecrosis in 
vivo and show a potent Ca2+-independent membrane-damaging activity in vitro 
(Lomonte et al., 2009). Although the involvement of a skeletal muscle protein acceptor 
in the process of sPLA2-induced myotoxicity cannot be ruled out, a considerable body 
of evidence has been accumulated indicating that the myotoxic effects are a 
consequence of a Ca2+-independent protein-lipid interaction that causes direct damage 
of the plasma membrane of target muscle cells and may allow entry of extracellular Ca2+ 
and irreversible cell damage (Cintra-Francischinelli et al., 2010; Lomonte et al., 2009; 
Rufini et al., 1992). The calcium-independent, and thus enzymatic activity-independent, 
mechanism of membrane damage is also supported by experiments in which inhibition 
of certain enzymatically active Asp49 myotoxic sPLA2s did not eliminate their myotoxic 
activity (Soares et al., 2001).  
We recently described the first example of restoration of activity in AtnL or in any 
enzymatically inactive Ser49/Lys49 sPLA2 homologue (Petan et al., 2007). We prepared two 
enzymatically active quaternary mutants of AtnL (H28Y/L31V,W/N33G/S49D), differing at 
position 31. Although Asn33 is not directly involved in Ca2+ coordination, we suspected that 
it might have a negative impact on the optimal local structure of the Ca2+-binding loop. We 
therefore replaced it with a glycine residue, which is very often found at this position in 
catalytically active sPLA2s, as well as in Atxs. Val31 was present in the AtnLYVGD mutant in 
order to recreate the Ca2+-binding loop of Atxs, while the AtnLYWGD mutant had Trp31 in 
order to enhance its membrane binding affinity, and thus enzymatic activity, as previously 
shown in the case of the AtxAV31W mutant described above. The successful restoration of 
enzymatic activity by such a small number of substitutions indicates that, apart from the 
residues involved in Ca2+ coordination, the remainder of the substrate-binding and catalytic 
network of AtnL is very well conserved. Apparently, in evolution, Lys49 and Ser49 sPLA2 
myotoxins have lost their Ca2+-binding ability and enzymatic activity through subtle 
changes in the Ca2+-binding network alone, without affecting the rest of the catalytic 
machinery. Our results strongly suggest that these changes were selected for their Ca2+-
independent membrane-damaging ability and increase the specificity of their myotoxic 
activity. Although the restoration of enzymatic activity in AtnL increased its cytotoxic 
potency and lethality in general, it had a negative effect on its Ca2+-independent mechanism 
of membrane damage and on its ability to specifically target differentiated muscle cells in 
vitro. Given that AtnL shares a high level of identity with AtxA (74%), it was not surprising 
that the enzymatically active mutants of AtnL displayed a combination of the properties of 
both toxins. In other words, the restoration of enzymatic activity of AtnL reduced its ability 
to act as a potent and specific myotoxic molecule. The latter supports the idea of an 
evolutionary specialization of Ser49/Lys49 sPLA2 homologues to perform the role of 
abundant and weakly lethal, but specific, muscle-targeting toxins in the arsenal of 
pharmacologically active molecules found in snake venom. 
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7. Future perspectives 
Recently, we have been able to introduce a free cysteine residue into the molecule of AtxA 
by substituting Asn79 by Cys at the turn of the antiparallel ß-sheet. This mutation allowed 
for specific labelling of the neurotoxin molecule by either fluorescent or nanogold probes 
(Pražnikar et al., 2008, 2009). The conjugates were less toxic than the wild-type toxin, but 
retained its basic properties. They have proved to be a valuable tool in the study of 
presynaptic neurotoxicity. As an illustration, we have provided evidence that AtxA, a 
neurotoxic snake venom sPLA2, is indeed internalized into mammalian (mouse) motor 
nerve terminals (Logonder et al., 2009). 
We believe that similar approaches can be used in further protein engineering of Atxs and 
also other ß-ntxs, especially in monitoring their trafficking and cellular action (enzymatic 
activity, binding to protein target molecules). This should finally lead to a complete 
understanding of the molecular mechanism of presynaptic toxicity of sPLA2 neurotoxins, 
which may also open the way for better medical treatment of snake envenomation. 
Moreover, similar research approaches can also be exploited in the studies of homologous 
mammalian sPLA2s whose biological roles are still to be clarified. 
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